298 related articles for article (PubMed ID: 9681085)
1. A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer.
Masters GA; Mauer AM; Hoffman PC; Wyka D; Samuels BL; Krauss SA; Watson S; Golomb H; Vokes EE
Ann Oncol; 1998 Jun; 9(6):677-80. PubMed ID: 9681085
[TBL] [Abstract][Full Text] [Related]
2. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
[TBL] [Abstract][Full Text] [Related]
3. Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies.
Hoffman PC; Masters GA; Drinkard LC; Krauss SA; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Jun; 23(3 Suppl 6):11-5. PubMed ID: 8677441
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of vinorelbine and ifosfamide in advanced non-small-cell lung cancer.
Masters GA; Hoffman PC; Hsieh A; Drinkard LC; Mick R; Samuels BL; Guaspari A; Golomb HM; Vokes EE
J Clin Oncol; 1997 Mar; 15(3):884-92. PubMed ID: 9060524
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with stage IIIB and IV non-small-cell lung cancer.
Fujita A; Takabatake H; Tagaki S; Sekine K
Cancer Chemother Pharmacol; 2000; 45(4):279-83. PubMed ID: 10755315
[TBL] [Abstract][Full Text] [Related]
6. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.
Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP
Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer.
Souquet PJ; Fournel P; Bohas CH; Fortune IC; Chatte G
Semin Oncol; 1996 Apr; 23(2 Suppl 5):8-10. PubMed ID: 8610239
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide and vinorelbine as first-line chemotherapy for advanced non-small cell lung carcinoma.
Vallejo C; Romero A; Perez J; Cuevas M; Lacava J; Sabatini C; Dominguez M; Rodriguez R; Barbieri M; Romero Acuña L; Romero Acuña J; Langhi M; Amato S; Salvadori M; Ortiz E; Machiavelli M; Leone B
Am J Clin Oncol; 1996 Dec; 19(6):584-8. PubMed ID: 8931677
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small-cell lung cancer.
Baldini E; Tibaldi C; Chella A; Angeletti CA; Silvano G; Andrei A; Algeri R; Conte PF
Ann Oncol; 1996 Sep; 7(7):747-9. PubMed ID: 8905035
[TBL] [Abstract][Full Text] [Related]
10. A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.
Kosmas C; Tsavaris NB; Makatsoris T; Onyenadum A; Vadiaka M; Stavroyianni N; Sepsas E; Dimitropoulos D; Rokana S; Kalofonos HP
Int J Cancer; 2002 Mar; 98(1):141-7. PubMed ID: 11857398
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
Palackdharry CS
Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532.
Perry MC; Ihde DC; Herndon JE; Grossbard ML; Grethein SJ; Atkins JN; Vokes EE; Green MR
Lung Cancer; 2000 Apr; 28(1):63-8. PubMed ID: 10704711
[TBL] [Abstract][Full Text] [Related]
13. Is cisplatin required for the treatment of non-small-cell lung cancer? Experience and preliminary results of a phase I/II trial with topotecan and vinorelbine.
Stupp R; Bodmer A; Duvoisin B; Bauer J; Perey L; Bakr M; Ketterer N; Leyvraz S
Oncology; 2001; 61 Suppl 1():35-41. PubMed ID: 11598413
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer.
Shepherd FA; Latreille J; Paul K; Eisenhauer E
Semin Oncol; 1996 Dec; 23(6 Suppl 16):84-90. PubMed ID: 9007130
[TBL] [Abstract][Full Text] [Related]
15. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
16. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.
Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE
Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.
Graziano SL; Valone FH; Herndon JE; Crawford J; Richards F; Rege VB; Clamon G; Green MR
Lung Cancer; 1996 Jun; 14(2-3):315-29. PubMed ID: 8794413
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II trial of paclitaxel and vinorelbine in advanced non-small cell lung cancer.
Grunberg SM; Dugan MC; Greenblatt MS; Ospina DJ; Valentine JW
Cancer Invest; 2005; 23(5):392-8. PubMed ID: 16193638
[TBL] [Abstract][Full Text] [Related]
19. Effect of vinorelbine, ifosfamide, and cisplatin combination chemotherapy in advanced non-small-cell lung cancer.
Ahn JB; Ko WK; Lee JG; Shim KY; Jeung HC; Park JO; Yoo NC; Kim BS; Kim SK; Kim SK; Kim JH
Am J Clin Oncol; 2000 Dec; 23(6):622-8. PubMed ID: 11202811
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in advanced non-small cell lung cancer.
Fujita A; Takabatake H; Tagaki S; Sekine K
Oncology; 1999; 56(4):301-7. PubMed ID: 10343194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
